Etelcalcetide Injection (Parsabiv™)

Covered: Parsabiv (etelcalcetide) is approved for adult patients with CKD on hemodialysis for secondary hyperparathyroidism and is excluded for pediatric patients and those not on hemodialysis or receiving cinacalcet within 7 days. Key requirements: current hemodialysis, corrected serum calcium ≥7.5 mg/dL with no hypocalcemia symptoms, initial PTH ≥300 pg/mL (reauthorization ≥100 pg/mL), IV bolus ≤15 mg up to three times weekly at dialysis end, documented labs/age/med history, and approvals limited to 12 months.

"Treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) undergoing hemodialysis."

Sign up to see full coverage criteria, indications, and limitations.